FDA accepts BMS’ Opdivo-Yervoy combo sBLA for colorectal cancer
The FDA has accepted Bristol Myers Squibb’s (BMS) supplemental biologics licence application (sBLA) for Opdivo and Yervoy combo.
The FDA has accepted Bristol Myers Squibb’s (BMS) supplemental biologics licence application (sBLA) for Opdivo and Yervoy combo.
What's Your Reaction?
